Screening Cardiometabolic Opportunities Using Transformative Echocardiography Artificial Intelligence (SCOUT Echo-AI) (NCT07216859)
🩺 Plain-English Summary (8th-Grade Level)
The goal of this prospective, multicenter, open-label, blinded end-point pragmatic study is to evaluate an artificial intelligence (AI)-augmented echocardiography screening approach for early detection of metabolic dysfunction associated steatotic liver disease (MASLD) and/or cirrhosis, in patients undergoing routine transthoracic echocardiograms (TTEs). The main question it aims to answer is to: 1. Evaluate notification responsiveness and rates of confirmatory testing for patients identified as high risk for having liver disease to determine whether optimized notifications increase timely confirmatory testing and treatment initiation versus standard of care assessment. 2. Compare time to diagnosis, treatment uptake, and clinical outcomes (hospitalizations, incident ASCVD, mortality) between cohorts identified as high risk by the AI algorithm and comparison groups to determine whether AI guided screening shortens time to diagnosis and increases appropriate treatment.
Who can join: Review the eligibility criteria below.
Location: Cedars-Sinai Medical Center — Los Angeles, California
Age range: 18 Years
🧪 Interventions in This Study
- AI-Enabled Identification (EchoNet-Liver) (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (6 Sites)
- Cedars-Sinai Medical Center — Los Angeles, California
- UCLA — Los Angeles, California
- Stanford Healthcare — Palo Alto, California
- Kaiser Permanente — Pleasanton, California
- Northwestern Medicine — Chicago, Illinois
- Massachusetts General Hospital — Boston, Massachusetts
📞 Contact the Study Coordinator
Phone: (310) 423-3475
Email: Alan.Kwan@cshs.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
- Effect of Ketone Esters on Liver Fat Content and Metabolic Function — St Louis, Missouri
- Development of a Quantifiable Ultrasound Biomarker for Hepatic Steatosis — Seattle, Washington
- Pediatric Metabolic Dysfunction-associated Steatotic Liver Disease and Food Insecurity — San Francisco, California
- A Study to Evaluate the Use of Resmetirom in Participants With MASLD and HIV — Birmingham, Alabama
- Food Insecurity and MASLD: A Fruit and Vegetable Intervention Study — San Francisco, California
Explore by condition: All MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.